Abvc Biopharma

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapeutic solutions in oncology/hematology, central nervous system (CNS), and ophthalmology. The company has positioned its operations in the drug development phase, transitioning promising drugs from the laboratory to the market, known as the translational stage. The drugs ABVC considers are typically plant-derived and have successfully completed preclinical, disease animal model, and Phase I safety studies at world-class research institutions. After reviewing relevant data on new drug candidates, ABVC enters into licensing agreements with research institutions, submits applications to health authorities such as the U.S. FDA, Australian TGA, and Taiwan TFDA to initiate Phase II trials, and seeks to collaborate with prestigious principal investigators in the U.S., Australia, and/or Taiwan for clinical trials. Upon successful completion of Phase II trials, ABVC seeks partners (usually large pharmaceutical companies) to complete Phase III studies, submit New Drug Applications (NDAs), and commercialize the drugs after obtaining FDA approval.